Abdellatif Tazi

Abdellatif Tazi

Auto-generated profile, based on publicly available information

Abdellatif Tazi

Université Paris Cité, Institut Cochin, UMR INSERM U1016-CNRS 8104, Phagocytes and Tumour Immunology Lab, Centre National des Référence des Histiocytoses, Service de Pneumologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2022 in Blood
Verified
Journal Article
Open access
PDF file
GGGaurav Goyal
Gaurav Goyal
ATAbdellatif Tazi
Abdellatif Tazi
RGRonald S. Go
Ronald S. Go
KRKaren L. Rech
Karen L. Rech
JPJennifer L. Picarsic
Jennifer L. Picarsic
MGMichael Girschikofsky
Michael Girschikofsky
Langerhans cell histiocytosis (LCH) can affect children and adults with a wide variety of clinical manifestations, including unifocal, single-system multifocal, single-system pulmonary (smoking-associated), or multisystem disease. The existing paradigms in the management of LCH in adults are mostly derived from the pediatric literature. Over the last decade, the discovery of clonality and MAPK-ERK pathway mutations in most cases led to the recognition of LCH as a hematopoietic neoplasm, opening the doors for treatment with targeted therapies. These advances have necessitated an update of the existing recommendations for the diagnosis and treatment of LCH in adults. This document presents consensus recommendations that resulted from the discussions at the annual Histiocyte Society meeting in 2019, encompassing clinical features, classification, diagnostic criteria, treatment algorithm, and response assessment for adults with LCH. The recommendations favor the use of 18F-Fluorodeoxyglucose positron emission tomography-based imaging for staging and response assessment in the majority of cases. Most adults with unifocal disease may be cured by local therapies, while the first-line treatment for single-system pulmonary LCH remains smoking cessation. Among patients not amenable or unresponsive to these treatments and/or have multifocal and multisystem disease, systemic treatments are recommended. Preferred systemic treatments in adults with LCH include cladribine or cytarabine, with the emerging role of targeted (BRAF and MEK inhibitor) therapies. Despite documented responses to treatments, many patients struggle with a high symptom burden from pain, fatigue, and mood disorders that should be acknowledged and managed appropriately.

22 May 2017 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
ATAbdellatif Tazi
Abdellatif Tazi
GLGwenaël Lorillon
Gwenaël Lorillon
JHJulien Haroche
Julien Haroche
ANAntoine Neel
Antoine Neel
SDStéphane Dominique
Stéphane Dominique
SCSylvie Chevret
Sylvie Chevret
Vinblastine is the standard treatment for children with Langerhans cell histiocytosis (LCH). Whether this treatment could be extended to adults with LCH is questionable. This retrospective multicenter study included 35 adult patients (median age 33 years; 23 men; 80% with multisystem LCH) who were treated with vinblastine + steroids as a first-line chemotherapy and followed for a median time of 83 months. The objectives were to determine the overall response rate (based on the Histiocyte Society criteria), disease reactivation rate, toxicity, permanent consequences, and survival rate corresponding to this treatment. The lung involvement outcome was based on serial lung function tests. The distribution of right-censored end points was estimated by the Kaplan-Meier method. Univariate Cox model with time-fixed and time-varying covariates was used for the predictive analysis of reactivation in the responders. Univariate analyses of risk factors for neurotoxicity were based on nonparametric Wilcoxon rank sum tests and exact Fisher tests. The median duration of the first course of vinblastine was 7.6 months, with a median cumulative dose of 160 mg [IQR 120–212]. Seventy percent of the patients were responders at the end of this treatment. Subsequently, LCH reactivation occurred with a 5-year cumulative incidence of 40%. During the study, 27 reactivations were observed in 17 patients, and half of these episodes were retreated with vinblastine. At the end of the last vinblastine treatment, 70% of the patients were responders. None of the patients with impaired lung function improved. No grade 3–4 peripheral neuropathy was observed. At the final vinblastine treatment, permanent LCH consequences, primarily pituitary stalk involvement, were present in 15 (43%) patients, and all were present at the time of vinblastine initiation. The 10-year survival rate was 86.2% (95CI, 71.8–100%), and the 2 patients who died from LCH had risk organ localizations. Vinblastine is an effective and well-tolerated first-line treatment for adult LCH except in patients with lung involvement and impaired lung function. However, a significant portion of patients experienced LCH reactivation during long-term follow up. As in childhood LCH, the presence of risk organ involvement has a negative impact on patient prognosis.

20 September 2016 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
JOJulie Obert
Julie Obert
LVLaetitia Vercellino
Laetitia Vercellino
AGAxel Van Der Gucht
Axel Van Der Gucht
CMConstance de Margerie-Mellon
Constance de Margerie-Mellon
EBEmmanuelle Bugnet
Emmanuelle Bugnet
ATAbdellatif Tazi
Abdellatif Tazi

6 September 2017 in European Respiratory Review
Verified
Journal Article
Open access
PDF file
GLGwenaël Lorillon
Gwenaël Lorillon
ATAbdellatif Tazi
Abdellatif Tazi
Pulmonary Langerhans cell histiocytosis (PLCH) is a rare sporadic cystic lung disease of unknown aetiology that is characterised by the infiltration and destruction of the wall of distal bronchioles by CD1a+Langerhans-like cells. In adults, PLCH is frequently isolated and affects young smokers of both sexes. Recent multicentre studies have led to the more standardised management of patients in clinical practice. Smoking cessation is essential and is occasionally the only suitable intervention. Serial lung function testing is important because a significant proportion of patients may experience an early decline in forced expiratory volume in 1 s and develop airflow obstruction. Cladribine was reported to dramatically improve progressive PLCH in some patients. Its efficacy and tolerance are currently being evaluated. Patients who complain of unexplained dyspnoea with decreased diffusing capacity of the lung for carbon monoxide should be screened for pulmonary hypertension by Doppler echocardiography, which must be confirmed by right heart catheterisation. Lung transplantation is a therapeutic option for patients with advanced PLCH.The identification of theBRAFV600Emutation in approximately half of Langerhans cell histiocytosis lesions, including PLCH, and other mutations of the mitogen-activated protein kinase (MAPK) pathway in a subset of lesions has led to targeted treatments (BRAF and MEK (MAPK kinase) inhibitors). These treatments need to be rigorously evaluated because of their potentially severe side-effects.

5 December 2019 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
FJFanélie Jouenne
Fanélie Jouenne
SCSylvie Chevret
Sylvie Chevret
EBEmmanuelle Bugnet
Emmanuelle Bugnet
ECEmmanuelle Clappier
Emmanuelle Clappier
GLGwenaël Lorillon
Gwenaël Lorillon
ATAbdellatif Tazi
Abdellatif Tazi
The clinical significance of theBRAFV600Emutation in adult Langerhans cell histiocytosis (LCH), including pulmonary Langerhans cell histiocytosis (PLCH), is not well understood. Similarly, the spectrum of molecular alterations involved in adult LCH has not been fully delineated. To address these issues, we genotyped a large number of adult LCH biopsies and searched for an association of identified molecular alterations with clinical presentation and disease outcome.Biopsies from 117 adult LCH patients, 83 with PLCH (median age 36.4 years, 56 females, 38 multisystem disease, 79 single system disease, 65 current smokers) were genotyped for theBRAFV600Emutation. In 69 cases, LCH lesions were also genotyped by whole-exome sequencing (WES) or targeted gene panel next-generation sequencing (NGS). Cox models were used to estimate the association of baseline characteristics with the hazard of LCH progression.MAPK pathway alterations were detected in 59 out of 69 cases (86%) (BRAFV600Emutation: 36%,BRAFN486_P490deletion: 28%,MAP2K1mutations: 15%, isolatedNRASQ61mutations: 4%), whileKRASmutations were virtually absent in PLCH lesions. TheBRAFV600Emutation was not associated with LCH presentation at diagnosis, including smoking status and lung function, in PLCH patients.BRAFV600Estatus did not influence the risk of LCH progression over time.Thus, MAPK alterations are present in most lesions from adult LCH patients, particularly in PLCH. Unlike reports in paediatric LCH,BRAFV600Egenotyping did not provide additional information on disease outcome. The search for alterations involved in the MAPK pathway, includingBRAFdeletions, is useful for guiding targeted treatment in selected patients with refractory progressive LCH.

25 April 2018 in Respiratory Research
Verified
Journal Article
Open access
PDF file
BSBerenice Soyez
Berenice Soyez
RBRaphael borie
Raphael borie
CMCédric Ménard
Cédric Ménard
JCJacques Cadranel
Jacques Cadranel
LCLeonidas Chavez
Leonidas Chavez
BCBruno Crestani
Bruno Crestani
Whole lung lavage is the current standard therapy for pulmonary alveolar proteinosis (PAP) that is characterized by the alveolar accumulation of surfactant. Rituximab showed promising results in auto-immune PAP (aPAP) related to anti-GM-CSF antibody. We aimed to assess efficacy of rituximab in aPAP in real life and all patients with aPAP in France that received rituximab were retrospectively analyzed. Thirteen patients were included. No patients showed improvement 6 months after treatment, but, 4 patients (30%) presented a significant decrease of alveolar-arterial difference in oxygen after 1 year. One patient received lung transplantation and one patient was lost of follow-up within one year. Although a spontaneous improvement cannot be excluded in these 4 patients, improvement was more frequent in patients naïve to prior specific therapy and with higher level of anti-GM-CSF antibodies evaluated by ELISA. No serious adverse event was evidenced. These data do not support rituximab as a second line therapy for patients with refractory aPAP.